abiraterone has been researched along with Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrahamsson, M; Falkenius, J; Henriksson, R; Lindquist, M; Lööv, SÅ; Norin, S; Öhman, D | 1 |
| Blank, PR; Puri, D; Szucs, TD | 1 |
| Goozner, M | 1 |
3 other study(ies) available for abiraterone and Melanoma
| Article | Year |
|---|---|
[Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice].
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bevacizumab; Breast Neoplasms; Colorectal Neoplasms; Drug Utilization; Humans; Ipilimumab; Male; Melanoma; Neoplasms; Nitriles; Palliative Care; Phenylthiohydantoin; Pilot Projects; Prostatic Neoplasms; Radium; Registries; Survival Rate; Sweden; Withholding Treatment | 2017 |
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.
Topics: Algorithms; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Immunosuppressive Agents; Ipilimumab; Lupus Erythematosus, Systemic; Male; Melanoma; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Skin Neoplasms; Tissue Extracts | 2014 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |